 Albaha Barqawi
Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 14 | 2021 | 999 | 1.930 |
Why?
| | Cryotherapy | 3 | 2021 | 16 | 1.750 |
Why?
| | Prostate | 3 | 2020 | 173 | 0.730 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 147 | 0.670 |
Why?
| | Imaging, Three-Dimensional | 2 | 2020 | 530 | 0.580 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 957 | 0.450 |
Why?
| | Lower Urinary Tract Symptoms | 1 | 2013 | 55 | 0.400 |
Why?
| | Symptom Assessment | 1 | 2013 | 125 | 0.390 |
Why?
| | Ultrasound, High-Intensity Focused, Transrectal | 1 | 2011 | 2 | 0.370 |
Why?
| | Prostate-Specific Antigen | 6 | 2020 | 160 | 0.320 |
Why?
| | Ultrasonography, Interventional | 2 | 2020 | 130 | 0.230 |
Why?
| | Self Medication | 1 | 2004 | 10 | 0.220 |
Why?
| | Prazosin | 1 | 2004 | 23 | 0.220 |
Why?
| | Plant Preparations | 1 | 2004 | 32 | 0.220 |
Why?
| | Prostatic Hyperplasia | 1 | 2004 | 41 | 0.210 |
Why?
| | Palpation | 1 | 2003 | 11 | 0.210 |
Why?
| | Phytotherapy | 1 | 2004 | 79 | 0.210 |
Why?
| | Cryptorchidism | 1 | 2003 | 14 | 0.210 |
Why?
| | Anticarcinogenic Agents | 1 | 2004 | 77 | 0.210 |
Why?
| | Complementary Therapies | 1 | 2004 | 87 | 0.200 |
Why?
| | Testis | 1 | 2003 | 144 | 0.200 |
Why?
| | Vitamins | 1 | 2004 | 173 | 0.200 |
Why?
| | Combined Modality Therapy | 2 | 2021 | 1201 | 0.190 |
Why?
| | Adenocarcinoma | 2 | 2007 | 893 | 0.180 |
Why?
| | Neoplasm Staging | 1 | 2004 | 1282 | 0.170 |
Why?
| | Kallikreins | 1 | 2020 | 29 | 0.170 |
Why?
| | Image-Guided Biopsy | 1 | 2020 | 37 | 0.170 |
Why?
| | Urination Disorders | 2 | 2013 | 13 | 0.160 |
Why?
| | Dietary Supplements | 1 | 2004 | 532 | 0.160 |
Why?
| | Male | 17 | 2021 | 63759 | 0.160 |
Why?
| | Laparoscopy | 1 | 2003 | 447 | 0.150 |
Why?
| | Middle Aged | 9 | 2021 | 31177 | 0.140 |
Why?
| | Survival Rate | 1 | 2021 | 1872 | 0.130 |
Why?
| | Mass Screening | 1 | 2004 | 1192 | 0.130 |
Why?
| | Aged | 8 | 2020 | 22107 | 0.120 |
Why?
| | Pilot Projects | 1 | 2021 | 1597 | 0.120 |
Why?
| | Prospective Studies | 2 | 2021 | 7158 | 0.120 |
Why?
| | Andropause | 1 | 2013 | 5 | 0.110 |
Why?
| | Nocturia | 1 | 2013 | 7 | 0.110 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2005 | 155 | 0.110 |
Why?
| | Humans | 18 | 2021 | 129847 | 0.110 |
Why?
| | Case-Control Studies | 1 | 2021 | 3384 | 0.100 |
Why?
| | Urology | 1 | 2013 | 57 | 0.100 |
Why?
| | Dexamethasone | 2 | 2006 | 352 | 0.100 |
Why?
| | Prognosis | 1 | 2021 | 3773 | 0.100 |
Why?
| | Testosterone | 2 | 2013 | 372 | 0.100 |
Why?
| | Biopsy | 2 | 2007 | 1089 | 0.100 |
Why?
| | Follow-Up Studies | 1 | 2021 | 4896 | 0.090 |
Why?
| | Quality of Life | 2 | 2020 | 2695 | 0.080 |
Why?
| | Societies, Medical | 1 | 2013 | 759 | 0.080 |
Why?
| | Retrospective Studies | 4 | 2020 | 14553 | 0.080 |
Why?
| | Treatment Outcome | 3 | 2020 | 10241 | 0.070 |
Why?
| | Androgen Antagonists | 2 | 2006 | 79 | 0.070 |
Why?
| | Biopsy, Needle | 1 | 2008 | 187 | 0.070 |
Why?
| | Patient Selection | 1 | 2011 | 660 | 0.070 |
Why?
| | Prostatectomy | 1 | 2007 | 103 | 0.060 |
Why?
| | Myocardial Infarction | 1 | 2013 | 1021 | 0.060 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2006 | 1560 | 0.060 |
Why?
| | Cryosurgery | 1 | 2007 | 57 | 0.060 |
Why?
| | Carboplatin | 1 | 2006 | 139 | 0.060 |
Why?
| | Severity of Illness Index | 1 | 2013 | 2739 | 0.060 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2007 | 175 | 0.060 |
Why?
| | Stroke | 1 | 2013 | 1072 | 0.060 |
Why?
| | Orchiectomy | 1 | 2005 | 67 | 0.060 |
Why?
| | Doxazosin | 1 | 2004 | 2 | 0.060 |
Why?
| | Penile Erection | 1 | 2004 | 7 | 0.060 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2004 | 33 | 0.050 |
Why?
| | Finasteride | 1 | 2004 | 34 | 0.050 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 72 | 0.050 |
Why?
| | Selenium | 1 | 2004 | 36 | 0.050 |
Why?
| | Early Diagnosis | 1 | 2005 | 233 | 0.050 |
Why?
| | Seminal Vesicles | 1 | 2003 | 9 | 0.050 |
Why?
| | Inguinal Canal | 1 | 2003 | 10 | 0.050 |
Why?
| | Vas Deferens | 1 | 2003 | 19 | 0.050 |
Why?
| | Patient Care Planning | 1 | 2004 | 146 | 0.050 |
Why?
| | Peritoneal Cavity | 1 | 2003 | 31 | 0.050 |
Why?
| | Gastroschisis | 1 | 2003 | 21 | 0.050 |
Why?
| | Seminoma | 1 | 2003 | 18 | 0.050 |
Why?
| | Radiation Injuries | 1 | 2004 | 135 | 0.050 |
Why?
| | Anus, Imperforate | 1 | 2003 | 24 | 0.050 |
Why?
| | Cyclooxygenase 2 | 1 | 2004 | 176 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2003 | 234 | 0.050 |
Why?
| | Forecasting | 1 | 2005 | 361 | 0.050 |
Why?
| | Isoenzymes | 1 | 2004 | 301 | 0.050 |
Why?
| | Ultrasonography | 1 | 2007 | 713 | 0.050 |
Why?
| | Hypospadias | 1 | 2003 | 28 | 0.050 |
Why?
| | Drug Utilization | 1 | 2004 | 171 | 0.050 |
Why?
| | Vitamin D | 1 | 2006 | 380 | 0.050 |
Why?
| | Chromosome Aberrations | 1 | 2003 | 140 | 0.050 |
Why?
| | Carcinoma | 1 | 2004 | 213 | 0.050 |
Why?
| | United States | 2 | 2013 | 13913 | 0.050 |
Why?
| | Testicular Neoplasms | 1 | 2003 | 102 | 0.050 |
Why?
| | Urinary Bladder, Neurogenic | 1 | 2002 | 36 | 0.050 |
Why?
| | Health Surveys | 1 | 2004 | 495 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2007 | 7066 | 0.040 |
Why?
| | Antioxidants | 1 | 2004 | 558 | 0.040 |
Why?
| | Sulfonamides | 1 | 2004 | 497 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2004 | 1214 | 0.040 |
Why?
| | Family | 1 | 2004 | 646 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2004 | 1368 | 0.040 |
Why?
| | Adult | 3 | 2007 | 35634 | 0.040 |
Why?
| | Research Design | 1 | 2004 | 1045 | 0.040 |
Why?
| | Antibodies, Monoclonal | 1 | 2004 | 1368 | 0.040 |
Why?
| | Membrane Proteins | 1 | 2004 | 1119 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2004 | 1264 | 0.030 |
Why?
| | Colorado | 1 | 2004 | 4410 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2004 | 2045 | 0.030 |
Why?
| | Coronary Angiography | 1 | 2013 | 306 | 0.020 |
Why?
| | Mortality | 1 | 2013 | 308 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2004 | 5437 | 0.020 |
Why?
| | Risk | 1 | 2013 | 860 | 0.020 |
Why?
| | Risk Factors | 1 | 2004 | 9801 | 0.020 |
Why?
| | Infant | 1 | 2003 | 9018 | 0.020 |
Why?
| | Child, Preschool | 1 | 2003 | 10522 | 0.020 |
Why?
| | Coronary Artery Disease | 1 | 2013 | 680 | 0.020 |
Why?
| | Medical History Taking | 1 | 2007 | 118 | 0.020 |
Why?
| | Child | 2 | 2003 | 20962 | 0.020 |
Why?
| | Syndrome | 1 | 2007 | 338 | 0.020 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2008 | 252 | 0.020 |
Why?
| | Pedigree | 1 | 2007 | 483 | 0.020 |
Why?
| | Gynecomastia | 1 | 2005 | 6 | 0.020 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2005 | 64 | 0.010 |
Why?
| | Muscular Diseases | 1 | 2005 | 109 | 0.010 |
Why?
| | Hot Flashes | 1 | 2005 | 82 | 0.010 |
Why?
| | Trastuzumab | 1 | 2004 | 100 | 0.010 |
Why?
| | Adolescent | 1 | 2003 | 20451 | 0.010 |
Why?
| | Anemia | 1 | 2005 | 162 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 2004 | 402 | 0.010 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2004 | 307 | 0.010 |
Why?
| | Cohort Studies | 1 | 2013 | 5444 | 0.010 |
Why?
| | Gastrointestinal Diseases | 1 | 2005 | 198 | 0.010 |
Why?
| | Bladder Exstrophy | 1 | 2002 | 17 | 0.010 |
Why?
| | Cystostomy | 1 | 2002 | 9 | 0.010 |
Why?
| | Osteoporosis | 1 | 2005 | 231 | 0.010 |
Why?
| | Veterans | 1 | 2013 | 1383 | 0.010 |
Why?
| | Receptor, ErbB-2 | 1 | 2004 | 325 | 0.010 |
Why?
| | Urethra | 1 | 2002 | 52 | 0.010 |
Why?
| | Animals | 1 | 2004 | 35409 | 0.010 |
Why?
| | Neural Tube Defects | 1 | 2002 | 58 | 0.010 |
Why?
| | Transplantation, Autologous | 1 | 2002 | 213 | 0.010 |
Why?
| | Body Composition | 1 | 2005 | 649 | 0.010 |
Why?
| | Spinal Dysraphism | 1 | 2002 | 70 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2004 | 1690 | 0.010 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2004 | 753 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2004 | 756 | 0.010 |
Why?
| | Disease Progression | 1 | 2004 | 2628 | 0.010 |
Why?
| | Mental Disorders | 1 | 2005 | 1035 | 0.010 |
Why?
|
|
Barqawi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|